dioleoyl-phosphatidylethanolamine and Teratocarcinoma

dioleoyl-phosphatidylethanolamine has been researched along with Teratocarcinoma* in 1 studies

Other Studies

1 other study(ies) available for dioleoyl-phosphatidylethanolamine and Teratocarcinoma

ArticleYear
IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
    Journal of immunology (Baltimore, Md. : 1950), 1999, Dec-15, Volume: 163, Issue:12

    We have evaluated whether i.p. murine ovarian tumors could be treated with an IL-2 plasmid DNA complexed with the cationic lipid, (+/-)-N-(2-hydroxyethyl)-N,N-dimethyl-2, 3-bis(tetradecyloxy)-1-propanaminium bromide/dioleoylphosphatidylethanolamine (DMRIE/DOPE). Reporter gene studies were initially conducted in which mice bearing i.p. murine ovarian teratocarcinoma (MOT) were injected i.p. with reporter gene plasmid DNA (pDNA):DMRIE/DOPE. Histochemical analyses revealed that transfection occurred primarily in the tumor cells of the ascites, with only a minority of other ascitic cells or surrounding tissues transfected. IL-2 levels in the MOT ascites were determined after i. p. injection of either IL-2 pDNA:DMRIE/DOPE or recombinant IL-2 protein. IL-2 was detected in tumor ascites for up to 10 days after a single i.p. injection of IL-2 pDNA:DMRIE/DOPE, but was undetectable 24 h after a single i.p. injection of IL-2 protein. In an antitumor efficacy study, MOT tumor-bearing mice injected i.p. with IL-2 pDNA:DMRIE/DOPE on days 5, 8, and 11 after tumor cell implant had a significant inhibition of tumor ascites (p = 0.001) as well as a significant increase in survival (p = 0.008). A cytokine profile of the MOT tumor ascites revealed that mice treated with IL-2 pDNA:DMRIE/DOPE had an IL-2-specific increase in the levels of IFN-gamma and GM-CSF. Taken together, these findings indicate that i. p. treatment of ovarian tumors with IL-2 pDNA:DMRIE/DOPE can lead to an increase in local IL-2 levels, a change in the cytokine profile of the tumor ascites, and a significant antitumor effect.

    Topics: Animals; Antineoplastic Agents; Ascites; Cytokines; DNA, Bacterial; Dose-Response Relationship, Immunologic; Female; Growth Inhibitors; Injections, Intraperitoneal; Interleukin-2; Lipids; Mice; Mice, Inbred C3H; Mice, Nude; Ovarian Neoplasms; Phosphatidylethanolamines; Plasmids; Quaternary Ammonium Compounds; Teratocarcinoma

1999